These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Analyses of the cardiac action of the bradycardic agent, AQ-A 39, by use of isolated, blood-perfused dog-heart preparations. Kawada M, Satoh K, Taira N. J Pharmacol Exp Ther; 1984 Feb; 228(2):484-90. PubMed ID: 6694121 [Abstract] [Full Text] [Related]
7. Selectivity of alinidine, a bradycardic agent, for SA nodal automaticity versus other cardiac activities in isolated, blood-perfused dog-heart preparations. Kawada M, Satoh K, Taira N. Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):88-102. PubMed ID: 6517649 [Abstract] [Full Text] [Related]
10. Effects of the new dihydropyridine derivative 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 6-(5-phenyl-3-pyrazolyloxy)hexyl ester on the cardiohemodynamics and the energy metabolism of ischemic myocardium. Imai H, Matsui K, Ochi S, Nakazawa M, Nakagawa Y, Imai S. Arzneimittelforschung; 1987 Dec; 37(12):1348-52. PubMed ID: 3449062 [Abstract] [Full Text] [Related]
12. Cardiovascular profile of Bay K 8644, a presumed calcium channel activator, in the dog. Wada Y, Satoh K, Taira N. Naunyn Schmiedebergs Arch Pharmacol; 1985 Feb; 328(4):382-7. PubMed ID: 2581147 [Abstract] [Full Text] [Related]
13. Separation of the coronary vasodilator from the cardiac effects of PN 200-110, a new dihydropyridine calcium antagonist, in the dog heart. Wada Y, Satoh K, Taira N. J Cardiovasc Pharmacol; 1985 Feb; 7(1):190-6. PubMed ID: 2580142 [Abstract] [Full Text] [Related]
14. Effects of the new calcium antagonist monatepil on cardiac function and myocardial oxygen supply and demand in animals. Kataoka T, Nose I, Honda Y, Yamada T, Hatano N, Masuda Y, Hosoki K, Karasawa T. Arzneimittelforschung; 1993 Dec; 43(12):1303-9. PubMed ID: 8141817 [Abstract] [Full Text] [Related]
15. Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine, and verapamil. A comparative study of physiological responses and membrane receptor activity. Millard RW, Grupp G, Grupp IL, DiSalvo J, DePover A, Schwartz A. Circ Res; 1983 Feb; 52(2 Pt 2):I29-39. PubMed ID: 6831652 [Abstract] [Full Text] [Related]
17. Cardiac versus coronary dilator effects of SD-3211, a new nondihydropyridine calcium antagonist, in isolated, blood-perfused dog hearts. Yoneyama F, Yamada H, Satoh K, Taira N. Cardiovasc Drugs Ther; 1990 Dec; 4(6):1469-76. PubMed ID: 2081139 [Abstract] [Full Text] [Related]
18. Cardiac effects of the novel pyridazinone derivative 6-[4-[2-[3-(5-chloro-2-cyanophenoxy)-2-hydroxypropylamino]- 2- methylpropylamino]phenyl]-4,5-dihydro-5-methyl-3(2H) pyridazinone monoethyl maleate and its metabolite in isolated heart preparations of guinea pigs and dogs. Ishimori T, Gotanda K, Sasaki T, Shinbo A, Asano H, Miyazawa K, Miyasaka K. Arzneimittelforschung; 1994 May; 44(5):583-8. PubMed ID: 7912931 [Abstract] [Full Text] [Related]
19. Coronary vasodilator compared to cardiac effects of PY 108-068, a new dihydropyridine vasodilator, on isolated, blood-perfused dog-heart preparations. Wada Y, Satoh K, Taira N. J Cardiovasc Pharmacol; 1984 May; 6(5):881-7. PubMed ID: 6209495 [Abstract] [Full Text] [Related]
20. Cardiac action of KB-944, a new calcium antagonist. Morita T, Ito K, Nose T. Arzneimittelforschung; 1982 May; 32(9):1053-5. PubMed ID: 6890825 [Abstract] [Full Text] [Related] Page: [Next] [New Search]